Table 1 Baseline characteristics
From: The risk of COVID-19 in survivors of domestic violence and abuse
Total number | Exposed group | Unexposed group |
|---|---|---|
(n=10,462) | (n=41,467) | |
Age [mean (SD)] | 42.38 (13.49) | 41.74 (13.42) |
Age [median (IQR)] | 41.00 (32.00–51.00) | 40.00 (32.00–50.00) |
Age categories [n (%)] | ||
16–30 years | 1797 (17.18) | 7831 (18.88) |
30–40 years | 3087 (29.51) | 12241 (29.52) |
40–50 years | 2561 (24.48) | 10131 (24.43) |
50–60 years | 1914 (18.29) | 7307 (17.62) |
60–70 years | 726 (6.94) | 2610 (6.29) |
>70 years | 377 (3.60) | 1347 (3.25) |
BMI [mean (SD)] | 27.09 (6.78) | 26.47 (6.60) |
BMI [median (IQR)] | 25.00 (22.00-30.00) | 24.00 (21.00-29.00) |
BMI categories [n (%)] | ||
Underweight (<18.5) | 433 (4.14) | 1200 (2.89) |
Normal weight (18.5–24.9) | 3493 (33.39) | 13913 (33.55) |
Overweight (25–30) | 2383 (22.78) | 7362 (17.75) |
Obese (>30) | 2412 (23.05) | 6970 (16.81) |
Missing | 1741 (16.64) | 12022 (28.99) |
Smoker categories [n (%)] | ||
Non-smoker | 3690 (35.27) | 19809 (47.77) |
Ex-smoker | 1807 (17.27) | 5331 (12.86) |
Smoker | 4317 (41.26) | 7989 (19.27) |
Missing | 648 (6.19) | 8338 (20.11) |
Ethnicity [n (%)] | ||
Caucasian | 5780 (55.25) | 13184 (31.79) |
South Asian | 456 (4.36) | 785 (1.89) |
Black Afro-Caribbean | 303 (2.90) | 510 (1.23) |
Mixed race | 117 (1.12) | 225 (0.54) |
Chinese/Middle Eastern/others | 1848 (17.66) | 6816 (16.44) |
Missing | 1958 (18.72) | 19947 (48.10) |
eGFR [mean (SD)] | 99.98 (18.39) | 100.04 (18.72) |
eGFR [median (IQR)] | 101.00 (88.00–112.00) | 101.00 (87.00–113.00) |
eGFR categories [n (%)] | ||
Stage 1/2 (>60 mL/min) | 7020 (67.10) | 17329 (41.79) |
Stage 3 (30–59 mL/min) | 135 (1.29) | 293 (0.71) |
Stage 4 (<30 mL/min) | 8 (0.08) | 33 (0.08) |
Missing | 3299 (31.53) | 23812 (57.42) |
Systolic BP [mean (SD)] | 120.42 (15.23) | 119.67 (14.55) |
Systolic BP [median (IQR)] | 120.00 (110.00–130.00) | 120.00 (110.00–130.00) |
Systolic BP categories [n (%)] | ||
Normal (<120 mm Hg) | 4463 (42.66) | 15294 (36.88) |
Prehypertension (120–129 mm Hg) | 2357 (22.53) | 8803 (21.23) |
Hypertension stage 1 (130–139 mm Hg) | 1529 (14.61) | 5159 (12.44) |
Hypertension stage 2 (140–149 mm Hg) | 1066 (10.19) | 3003 (7.24) |
Missing | 1047 (10.01) | 9208 (22.21) |
Other co-morbidities [n (%)] | ||
Hypertension | 2289 (21.88) | 6591 (15.89) |
Diabetes | 449 (4.29) | 881 (2.12) |
Cancer | 225 (2.15) | 614 (1.48) |
Cardiac diseases | 373 (3.57) | 627 (1.51) |
Myocardial infarction | 71 (0.68) | 109 (0.26) |
Heart failure | 43 (0.41) | 96 (0.23) |
Stroke/TIA | 205 (1.96) | 274 (0.66) |
Atrial fibrillation | 40 (0.38) | 79 (0.19) |
Peripheral vascular disease | 83 (0.79) | 147 (0.35) |
Chronic liver disease | 190 (1.82) | 167 (0.40) |
Mild liver disease | 185 (1.77) | 163 (0.39) |
Moderate/severe liver disease | 22 (0.21) | 14 (0.03) |
Neuron disease | 330 (3.15) | 674 (1.63) |
Parkinson’s disease | 10 (0.10) | 9 (0.02) |
Motor neuron disease | 1 (0.01) | 1 (0.00) |
Multiple sclerosis | 35 (0.33) | 92 (0.22) |
Epilepsy | 286 (2.73) | 572 (1.38) |
Myasthenia gravis | 2 (0.02) | 5 (0.01) |
Rheumatic diseases | 589 (5.63) | 1455 (3.51) |
SLE | 30 (0.29) | 38 (0.09) |
Rheumatoid arthritis | 82 (0.78) | 150 (0.36) |
Psoriasis | 489 (4.67) | 1283 (3.09) |
Dementia | 45 (0.43) | 64 (0.15) |
Severe respiratory disease | 69 (0.66) | 99 (0.24) |
Asthma | 2296 (21.95) | 5781 (13.94) |
COPD | 310 (2.96) | 296 (0.71) |
Solid organ transplant | 7 (0.07) | 23 (0.06) |
Prescriptions (any time prior to index date) [n (%)] | ||
Immunosuppressive drug therapies | 25 (0.24) | 70 (0.17) |